Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.

Gynecologic oncology - 1 Dec 2006

Mayr Doris, Hirschmann Astrid, Löhrs Udo, Diebold Joachim

Abstract excerpt

OBJECTIVE: Mutations of BRAF, a downstream mediator of K-RAS, have been described in serous borderline tumors of the ovary. Data concerning other types of ovarian tumors are scarce. Therefore, we assessed KRAS and BRAF mutation in a series of more than 100 different ovarian tumors. METHODS: Paraffin-embedded material, including invasive carcinomas, borderline tumors, benign lesions and implants, was used. BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Carcinoma, Endometrioid

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to DNA, Neoplasm

Share to Genes, ras

Share to Neoplasm Invasiveness

Share to Neoplasm Metastasis

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 16806438
DOI: 10.1016/j.ygyno.2006.05.029

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.PMID 16806438Read ↗

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Semantic proximity Read ↗

v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.Semantic proximity Read ↗

KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.Semantic proximity Read ↗

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.Semantic proximity Read ↗

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.Semantic proximity Read ↗

Endocervical-like (Müllerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

[Molecular pathology of epithelial ovarian neoplasias: from the phenotype-genotype correlation to new targets in diagnostics and therapy].Semantic proximity Read ↗

Origins and molecular pathology of ovarian cancer.Semantic proximity Read ↗

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.